-
Euro-Area Growth Slows to 0.4% While Employment Stalls
-
UK Economy Grows 0.7% in Third Quarter as Services Lead Expansion
-
US Wholesale Inflation Eases Monthly but Hits a Four-Year Annual High
-
India's Retail Inflation Reaches 6.09% as Food Prices Accelerate
-
India's Wholesale Inflation Jumps to 12.29% as Fuel Costs Surge
-
China's October Activity Data Reveal a Weak Start to the Fourth Quarter
-
Japan's Economy Edges Into Contraction as Costly Oil Weighs on Demand
-
Philippines Urges ASEAN and China to Accelerate South China Sea Code of Conduct
-
South Korea Launches Probe into NewJeans Contract Controversy
-
Met Office Issues Yellow Snow Warning for Nottinghamshire on Tuesday
-
UK Defence Secretary Warns Russia Nukes Not for Negotiation as HMS Vengeance Returns
-
Rescue Intellitech Expands Professional Decontamination Portfolio for Fire Departments with DeconWasher(TM) Pro S
-
GameSquare Holdings Reports 2026 Third Quarter Results with Revenue up 77% YoY and Net Income Reaches $10.1 Million
-
ValorPay UAB Goes Live on T2, the Eurosystem's Real-Time Settlement System
-
NuRAN Wireless Eliminates Floating-Price Preferred Overhang and Locks In a Fixed C$1.20 Conversion Price
-
CNS Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress in Establishing Transformative Therapeutic Pipeline
-
XCF Global Reports Third Quarter 2026 Financial Results & Affirms 2027 Outlook
-
NextSource Materials Appoints Eugene Lee as Chief Financial Officer
-
International Battery Metals Ltd. Reports Second Quarter of Fiscal Year 2027 Financial Results
-
Abasca Resources Engages Northern Arc Public Affairs to Advance Federal Engagement on the Loki Flake Graphite Project
-
AsiaFIN Holdings Corp. Announces Third Quarter 2026 Results, Reporting Strong Nine-Month Financial Performance with Improved Margins
-
Thalia Therapeutics PLC Announces Promising Interim Phase I Data for miRisten in AML
-
Strategic Metals Reports Promising Results From the Rusty and Ranch Projects
-
Golden Minerals Reports Third Quarter 2026 Financial Results
-
OBI Pharma Signs Collaboration and License Agreement with Novartis
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 16
-
Blue Chip Capital Group Announces Quotation of its Common Stock on the OTCID and Updates Status of Initial Regulatory Compliance
-
Cardiff Lexington Announces Third Quarter 2026 Financial Results
-
Emerging Growth Research Highlights Criticality of First Phosphate G7-Backed LFP Battery Onshoring Solution as Cleantech Sector Accelerates Post U.S. Midterms
-
Presidio Property Trust, Inc. Announces Earnings for the Quarter Ended September 30, 2026
-
Sekur Private Data Ltd. Provides Update on Expected Closing of Non-Brokered Private Placement
-
iFabric Corp Announces Record Revenues for Q3 2026 and the Nine Months Ended September 30, 2026
-
RenX Enterprises Reports Record Third Quarter Revenue of $4.49 Million, Up 27.6% Year Over Year
-
Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results
-
Gladstone Capital Corporation Earnings Call and Webcast Information
-
Sharecare Partners With HomeTown Health to Bring AskMD, Funded Through the GREAT Health Program, to More Rural Hospitals and Patients Across Georgia
-
Wi2Wi Reports 35% Revenue Growth to US$2.36M and Returns to Profitability with US$268K Net Income in Q3 2026
-
Ainos Reports Third Quarter 2026 Results and Highlights Expanding AI Nose Commercial Momentum
-
SMX Brings a New Level of Transparency to Gold Trading Through trueGold Technology
-
Westell Technologies, Inc. Announces Its Commencing a Tender Offer
-
MicroVision Lidar Powers Commercial Driverless Trucking at Scale with Kodiak AI
-
Expecting a Refund but Owe Back Taxes? Clear Start Tax Explains How the IRS Offset Program Takes It First
-
SMX: The Future of Gold Will Be Defined by What We Know About It -Powering Verified Trade and Tokenisation
-
Poll Shows Two-Thirds of New York Voters Support Lifting Charter School Cap
-
Park Jin-young Denies Cult Allegations Against Firstfruits Group
-
Downing Street Defends PM's Speechwriting After AI Photo Emerges
Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results
Mipletamig achieves 79% remission rate in high-risk TP53-mutated AML, nearly double the published historical benchmark
Ten of 47 patients receiving mipletamig combination therapy advances to potentially curative stem cell transplantation
Refined priming-dose regimen significantly reduces infusion-related reactions, marking important tolerability advance
Aptevo advances next generation trispecifics toward human testing, expanding opportunities beyond AML
SEATTLE, WA / ACCESS Newswire / November 16, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today reported financial results for the quarter ended September 30, 2026, and highlighted new clinical findings supporting mipletamig's potential in frontline acute myeloid leukemia (AML), progress in optimizing treatment tolerability, and continued advancement of its next-generation cancer treatment pipeline.
"We are entering an exciting period for Aptevo, with growing clinical evidence that reinforces our confidence in mipletamig and meaningful progress across our broader pipeline," said Jeff Lamothe, President and Chief Executive Officer of Aptevo. "We are seeing strong clinical activity in patients with some of the most difficult-to-treat forms of AML, patients advancing to potentially curative stem cell transplantation, and important improvements in tolerability. Each of these findings adds a new dimension to the mipletamig story and strengthens our conviction in its potential to become an important addition to frontline AML treatment. At the same time, we are advancing a new generation of cancer therapies designed to bring the power of our multispecific technology to more patients and more types of cancer. As we approach important clinical and development milestones, we believe Aptevo is increasingly well positioned to translate the strength of our science into meaningful opportunities for patients and long-term value for shareholders."
Business Highlights
- Mipletamig delivers a 79% remission rate in one of the hardest-to-treat forms of AML, nearly double a published historical benchmark. In September, Aptevo reported that 14 evaluable TP53-mutated patients treated with mipletamig in combination with venetoclax and azacitidine, including two patients from the previously completed dose expansion trial, 13 (93%) experienced clinical benefit. * Eleven patients achieved CR or CRi (79%), including nine complete remissions.
*Clinical benefit includes complete remission (CR), complete remission with incomplete hematologic recovery (CRi), partial response (PR) and morphologic leukemia-free state (MLFS).
These results are encouraging because patients with TP53-mutated AML have historically had limited treatment success. The 79% CR/CRi rate observed in evaluable patients treated with the mipletamig triplet compares favorably with a published 41% composite remission rate of intent-to-treat, treatment-naïve patients with poor-risk cytogenetics and TP53-mutated AML who received only venetoclax plus azacitidine.**
**Benchmark comparison based on Pollyea DA, et al. Clinical Cancer Research 2022;28(24):5272-5279. Comparison is to treatment-naïve patients with poor-risk cytogenetics and TP53-mutated AML treated with venetoclax plus azacitidine.
- Ten of 47 patients receiving mipletamig combination therapy advances to potentially curative stem cell transplantation. In October, Aptevo reported that ten of 47 evaluable frontline patients treated with mipletamig in combination with venetoclax and azacitidine (VEN+AZA) proceeded to allogeneic stem cell transplantation, a potentially curative treatment option. This includes nine patients from the ongoing Phase 1b RAINIER trial and one patient from the previously completed dose expansion trial. This finding is particularly encouraging in a patient population initially deemed unfit for intensive induction chemotherapy, where advanced age, underlying health conditions and other factors can limit treatment options.
- Aptevo significantly reduced infusion-related reactions through refinements to mipletamig's priming-dose regimen. The adjustment substantially improved tolerability, addressing an important clinical development priority. For patients already facing the challenges of AML treatment, fewer reactions may mean a more manageable treatment experience, while supporting continued advancement toward Phase 2.
- Mipletamig approaches a major development milestone as RAINIER nears completion of Phase 1b dose optimization. With study completion targeted by year-end 2026 and regulatory interaction planned for the first half of 2027, Aptevo is moving closer to the next phase of clinical development, bringing mipletamig another step toward its potential role in frontline AML treatment.
- Aptevo clears important development hurdles on the path toward human testing of its next generation trispecifics. Progress in manufacturing optimization supports the ability to produce therapeutics that perform more than one immune engaging job in a single molecule - reliably and at the scale needed for further development. This moves Aptevo closer to advancing new treatment candidates for solid tumors, expanding its opportunities beyond AML.
- Aptevo expands the potential of its technology to power multiple new cancer treatments. A new patent application covering Nectin-4 × PD-L1 dual-targeting technology could support both immune-based therapies and radiopharmaceuticals. The filing strengthens Aptevo's intellectual property strategy, creating opportunities to apply its technology across multiple cancer treatment approaches.
- Aptevo secures $4.5 million in additional financing to support its next development milestones. In August, existing warrant holders exercised warrants for 254,922 shares at a price of $4.03 per share and purchased 861,708 additional shares (or pre-funded warrants) at the same price in a private placement. Investors also received new warrants covering up to 5,583,150 shares at $4.03 per share, which would provide up to $22.5 million in additional proceeds if exercised. The transaction provides additional capital to advance mipletamig and the Company's next-generation pipeline, helping fund continued clinical and preclinical progress.
Third Quarter 2026 Financials
- Cash position: Cash and cash equivalents totaled $8.3 million as of September 30, 2026, compared with $9.8 million as of June 30, 2026.
- Net loss: Net loss for the third quarter of 2026 was $6.5 million, compared with $7.5 million for the third quarter of 2025.
- Financing activity: In August 2026, the company completed a warrant inducement and private placement that generated gross proceeds of approximately $4.5 million, or approximately $4.1 million net of $0.4 million in issuance costs.
- For additional APVO financial information and complete access to the company's filings, click here.
About Aptevo
Aptevo Therapeutics Inc. (Nasdaq:APVO) is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for the treatment of cancer. The Company's lead clinical candidate, mipletamig, is currently being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax and azacitidine. Mipletamig has received orphan drug designation for AML under the Orphan Drug Act.
In the solid tumor space, Aptevo's lead assets are focused on well-established targets to progress novel immunomodulatory platform backbones that are conditionally active only in the tumor.
This work includes advancing APVO451, a targeted trispecific immunotherapy candidate for solid tumors, and a strategic collaboration with Niowave to develop up to three radiopharmaceutical oncology programs. The first radiopharmaceutical program is expected to target nectin-4, a tumor-associated antigen expressed in multiple solid tumor types. Both preclinical molecules are expected to advance into investigational new drug (IND)-enabling studies in 2027.
The Company's eight pipeline candidates are created using its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platforms, which are designed to generate differentiated multispecific therapeutics. For more information, please visit www.aptevotherapeutics.com.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, statements regarding Aptevo's expectations about the activity, efficacy, safety, tolerability and durability of mipletamig, including in combination with venetoclax and azacitidine; statements related to the progress of the RAINIER trial, including statements related to anticipated clinical and regulatory milestones; statements related to a growing number of patients treated with the mipletamig triplet advancing to stem cell transplant and mipletamig's role in offering AML patients the possibility of long-term remission or cure, statements related to the responses observed in patients with TP53-mutated AML and whether further study of mipletamig in combination with venetoclax + azacitidine will continue to show clinical benefit in patients with TP53-mutated AML; whether Aptevo's strategy will translate into an improved overall survival rate in acute myeloid leukemia (AML); whether the mipletamig data in combination therapy will be indicative of later stage clinical trials; whether Aptevo's strategy will translate into improved overall survival in AML, especially among patient subgroups with poor prognosis; its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platform; development and continued development of Aptevo's current and potential future molecules, including Aptevo's trispecific candidates and their future development and efficacy with respect to addressing multiple solid tumor types; whether pre-clinical studies of Aptevo's trispecific candidates will show the desired anti-tumor efficacy, mechanism of action and safety profile and whether Aptevo's trispecific candidates will function with new mechanisms of action compared to our previous candidates and synergistically induce a biological response; the potential benefits, timing, scope and outcomes of the co-development collaboration with Niowave; and any statements containing the words "may," "continue to," "believes," "expects," "potential," "designed," "promising," "plans," "will" and similar expressions are intended to identify forward-looking statements.
These forward-looking statements are based on Aptevo's current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors are cautioned not to place undue reliance on any forward-looking statement. There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems; adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; and changes in regulatory, social, macroeconomic and political conditions. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, and its subsequent reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events or circumstances.
CONTACT:
Miriam Weber Miller
Vice President, Investor Relations & Corporate Communications
Aptevo Therapeutics
Email: [email protected] or [email protected]
Phone: 206-859-6628
SOURCE: Aptevo Therapeutics
View the original press release on ACCESS Newswire
F.Bennett--AMWN